PMCB Wutah bathi resik saben saham ing taun iki PharmaCyte

The year-over-year change in earnings per share demonstrates the business stability of PharmaCyte Biotech (PMCB) within the safe haven jurisdiction of the US. This trend is confirmed by the metric value of 0.00. Growth is supported by the unique Cell-in-a-Box system for localized tumor targeting. Revenues will be based on the commercialization of live-cell encapsulation technologies for the therapy of solid neoplasms.

Wutah bathi ing taun lumaku PharmaCyte (PMCB): kanggo periode 04.07.2022 - 10.11.2026

Rincian analitis lan laporan data perusahaan pharmacyte.com (PMCB)

- nilai saham lan prakiraan konsensus rega:

Rega bursa PharmaCyte Biotech, Inc.|PMCB - Bagan rega target

- data kapitalisasi pasar:

Biji pasar PharmaCyte Biotech, Inc.|PMCB - Nilai Perusahaan

- rincian nilai buku perusahaan:

Nilai Buku saben Saham PharmaCyte Biotech|PMCB - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih pharmacyte.com|PMCB - Total Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi PharmaCyte Biotech|PMCB - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang ekuitas PharmaCyte Biotech, Inc.|PMCB - Gunggung utang perusahaan|Rasio utang marang aset resik PharmaCyte Biotech, Inc.|PMCB - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan PharmaCyte Biotech|Rasio jangkoan perantara pharmacyte.com

- rincian bathi lan kelipatan pasar:

PMCB - Bathi resik perusahaan|Bathi mangsa ngarep PharmaCyte Biotech|PMCB - Pangali P/E|Pangali Forward P/E PharmaCyte Biotech, Inc.|PMCB - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PharmaCyte Biotech, Inc.|PMCB - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan PharmaCyte Biotech|PMCB - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan pharmacyte.com|PMCB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep PharmaCyte Biotech

Pambiji fundamental:PharmaCyte (PMCB)

Year-over-year earnings per share (EPS) dynamics are critical for assessing the issuer's financial stability. This indicator measures the percentage deviation of current EPS from the value of the same period last year, reflecting the actual efficiency of the business capitalization. For PharmaCyte Biotech (PMCB), current annual EPS growth serves as a marker of the company's ability to overcome biomanufacturing scaling challenges and FDA trial costs.

Pesaing langsung

Kacepetan wutah bathi saben saham ing taun lumaku TriSalus (TLSI)|Wutah bathi saben saham ing taun lumaku RenovoRx Corp